124 related articles for article (PubMed ID: 24146263)
1. Serological markers in psoriatic arthritis: promising tools.
Ramonda R; Modesti V; Ortolan A; Scanu A; Bassi N; Oliviero F; Punzi L
Exp Biol Med (Maywood); 2013 Dec; 238(12):1431-6. PubMed ID: 24146263
[TBL] [Abstract][Full Text] [Related]
2. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients.
Bevelacqua V; Libra M; Mazzarino MC; Gangemi P; Nicotra G; Curatolo S; Massimino D; Plumari A; Merito P; Valente G; Stivala F; La Greca S; Malaponte G
Int J Mol Med; 2006 Sep; 18(3):415-23. PubMed ID: 16865225
[TBL] [Abstract][Full Text] [Related]
3. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
4. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers.
Iervolino S; Di Minno MN; Peluso R; Lofrano M; Russolillo A; Di Minno G; Scarpa R
J Rheumatol; 2012 Mar; 39(3):568-73. PubMed ID: 22247361
[TBL] [Abstract][Full Text] [Related]
5. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
[TBL] [Abstract][Full Text] [Related]
7. Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)" in patients with psoriatic arthritis.
Kenar G; Yarkan H; Zengin B; Can G; Birlik M; Önen F
Rheumatol Int; 2018 Nov; 38(11):2069-2076. PubMed ID: 30194455
[TBL] [Abstract][Full Text] [Related]
8. Soluble biomarkers may differentiate psoriasis from psoriatic arthritis.
Chandran V
J Rheumatol Suppl; 2012 Jul; 89():65-6. PubMed ID: 22751596
[TBL] [Abstract][Full Text] [Related]
9. Differentiating Psoriatic Arthritis From Psoriasis Without Psoriatic Arthritis Using Novel Serum Biomarkers.
Cretu D; Gao L; Liang K; Soosaipillai A; Diamandis EP; Chandran V
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):454-461. PubMed ID: 28586166
[TBL] [Abstract][Full Text] [Related]
10. Is the health-related quality of life and functional status of patients with psoriatic arthritis worse than that of patients with psoriasis alone?
Tezel N; Yilmaz Tasdelen O; Bodur H; Gul U; Kulcu Cakmak S; Oguz ID; Karabulut E
Int J Rheum Dis; 2015 Jan; 18(1):63-9. PubMed ID: 24460852
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor in patients with psoriatic arthritis.
Fink AM; Cauza E; Hassfeld W; Dunky A; Bayer PM; Jurecka W; Steiner A
Clin Exp Rheumatol; 2007; 25(2):305-8. PubMed ID: 17543159
[TBL] [Abstract][Full Text] [Related]
12. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment.
Murdaca G; Colombo BM; Contini P; Puppo F
J Interferon Cytokine Res; 2012 Jun; 32(6):277-9. PubMed ID: 22480318
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
[TBL] [Abstract][Full Text] [Related]
14. Plasma YKL-40: a potential biomarker for psoriatic arthritis?
Jensen P; Wiell C; Milting K; Poggenborg RP; Østergaard M; Johansen JS; Skov L
J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):815-9. PubMed ID: 22621388
[TBL] [Abstract][Full Text] [Related]
15. [Clinical value of serum matrix metalloproteinase-3 in evaluating joint destruction and therapeutic effect in rheumatoid arthritis patients].
Li L; Cai B; Liao J; Yang B; Huang Z; Wang L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Sep; 29(9):966-9. PubMed ID: 24011160
[TBL] [Abstract][Full Text] [Related]
16. Plasma pentraxin 3 is associated with cardiovascular disease in hemodialysis patients.
Xu Y; Ding X; Zou J; Liu Z; Jiang S; Xu S; Shen B; Chen Y; Shan Y; Cao X
Ren Fail; 2011; 33(10):998-1004. PubMed ID: 22013933
[TBL] [Abstract][Full Text] [Related]
17. Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Deyab G; Hokstad I; Whist JE; Småstuen MC; Agewall S; Lyberg T; Bottazzi B; Meroni PL; Leone R; Hjeltnes G; Hollan I
PLoS One; 2017; 12(2):e0169830. PubMed ID: 28225768
[TBL] [Abstract][Full Text] [Related]
18. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set.
FitzGerald O; Helliwell P; Mease P; Mumtaz A; Coates L; Pedersen R; Nab H; Molta C
Ann Rheum Dis; 2012 Mar; 71(3):358-62. PubMed ID: 21989542
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of angiogenic cytokines in psoriatic arthritis and SAPHO syndrome.
Przepiera-Będzak H; Fischer K; Brzosko M
Pol Arch Med Wewn; 2013; 123(6):297-302. PubMed ID: 23711571
[TBL] [Abstract][Full Text] [Related]
20. Pentraxin 3 in serum and synovial fluid of patients with rheumatoid arthritis with and without autoantibodies.
Weitoft T; Larsson A; Saxne T; Manivel VA; Lysholm J; Knight A; Rönnelid J
Scand J Rheumatol; 2017 Sep; 46(5):346-352. PubMed ID: 27973973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
